Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2010

View Archived Issues

Cytomics claims novel antiproliferative agents for multidrug resistance cancer

GPR119 agonists for the treatment of obesity identified by iNovacia

Organon presents AMPA receptor agonists for neurodegenerative diseases

Bayer Schering Pharma discovers novel c-Met inhibitors for cancer therapy

Sunesis completes enrollment of phase Ib/II voreloxin trial

ACT Biotech confirms FDA acceptance of ACTB-1003 IND

Locked nucleic acid-based oligonucleotide suppresses HCV viremia in primates

Droxidopa restores contextual memory in mouse model of Down's syndrome

Cetuximab as first-line therapy for Menetrier's disease / News in Context

GlaxoSmithKline receives approval for Arepanrix H1N1 vaccine

Gentamicin induces readthrough of termination codons in Stuve-Wiedermann syndrome

Novartis obtains approval for new H1N1 flu vaccine

AFFiRiS discloses novel therapeutics for beta-amyloidoses

Novel monoamine reuptake inhibitors in development at SK Holdings

Inspire reports results of phase III Prolacria trial for dry eye

Somaxon provides update on Silenor NDA for the treatment of insomnia

Agennix expands phase III talactoferrin registration trial globally

Arzerra receives positive opinion for conditional approval in Europe for CLL

CytRx reports 2010 clinical and development milestones

GAA gene variants responsive to Pompe's disease candidate AT-2220 identified

OVATURE trial analysis to proceed following database lock

Sinovac presents recent developments for its vaccines

EMEA validates NicOx's MAA for naproxcinod in primary osteoarthritis

Pharming presents update on European CHMP's review of MAA for Rhucin in HAE

EMEA completes validation phase of MAA for Pfizer and Auxilium's Xiaflex

FDA grants marketing approval to Acorda's Ampyra to improve walking in MS patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...